110 related articles for article (PubMed ID: 3035076)
1. Serum and urine concentrations of oral bromovinyldeoxyuridine in humans as monitored by a bioassay system based on varicella-zoster virus focus inhibition.
Baba M; Shigeta S; De Clercq E
J Med Virol; 1987 May; 22(1):17-23. PubMed ID: 3035076
[TBL] [Abstract][Full Text] [Related]
2. Influence of various experimental conditions on the inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on varicella-zoster virus replication in cell culture.
Baba M; Shigeta S; De Clercq E
Tohoku J Exp Med; 1984 Aug; 143(4):441-9. PubMed ID: 6093286
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
De Clercq E; Descamps J; Ogata M; Shigeta S
Antimicrob Agents Chemother; 1982 Jan; 21(1):33-8. PubMed ID: 6282207
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
[TBL] [Abstract][Full Text] [Related]
5. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
De Clercq E
Med Res Rev; 2005 Jan; 25(1):1-20. PubMed ID: 15389733
[TBL] [Abstract][Full Text] [Related]
6. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.
De Clercq E
Biochem Pharmacol; 2004 Dec; 68(12):2301-15. PubMed ID: 15548377
[TBL] [Abstract][Full Text] [Related]
7. The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
De Clercq E
J Antimicrob Chemother; 1984 Aug; 14 Suppl A():85-95. PubMed ID: 6092320
[TBL] [Abstract][Full Text] [Related]
8. Potential of bromovinyldeoxyuridine in anticancer chemotherapy.
De Clercq E
Anticancer Res; 1986; 6(4):549-56. PubMed ID: 3752935
[TBL] [Abstract][Full Text] [Related]
9. β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.
De C; Liu D; Zheng B; Singh US; Chavre S; White C; Arnold RD; Hagen FK; Chu CK; Moffat JF
Antiviral Res; 2014 Oct; 110():10-9. PubMed ID: 25051026
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis induced by (E)-5-(2-bromovinyl)-2'-deoxyuridine in varicella zoster virus thymidine kinase-expressing cells is driven by activation of c-Jun/activator protein-1 and Fas ligand/caspase-8.
Tomicic MT; Friedrichs C; Christmann M; Wutzler P; Thust R; Kaina B
Mol Pharmacol; 2003 Feb; 63(2):439-49. PubMed ID: 12527816
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus.
Shigeta S; Yokota T; Iwabuchi T; Baba M; Konno K; Ogata M; De Clercq E
J Infect Dis; 1983 Mar; 147(3):576-84. PubMed ID: 6300257
[TBL] [Abstract][Full Text] [Related]
12. Effect of acyclovir combined with other antiherpetic agents on varicella zoster virus in vitro.
Biron KK; Elion GB
Am J Med; 1982 Jul; 73(1A):54-7. PubMed ID: 6285733
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activity of cyclosaligenyl prodrugs of the nucleoside analogue bromovinyldeoxyuridine against herpes viruses.
Meerbach A; Meier C; Sauerbrei A; Meckel HM; Wutzler P
Int J Antimicrob Agents; 2006 May; 27(5):423-30. PubMed ID: 16621459
[TBL] [Abstract][Full Text] [Related]
14. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.
Andrei G; Sienaert R; McGuigan C; De Clercq E; Balzarini J; Snoeck R
Antimicrob Agents Chemother; 2005 Mar; 49(3):1081-6. PubMed ID: 15728906
[TBL] [Abstract][Full Text] [Related]
15. Oral bromovinyldeoxyuridine therapy for herpes simplex and varicella-zoster virus infections in severely immunosuppressed patients: a preliminary clinical trial.
Tricot G; De Clercq E; Boogaerts MA; Verwilghen RL
J Med Virol; 1986 Jan; 18(1):11-20. PubMed ID: 3511181
[TBL] [Abstract][Full Text] [Related]
16. Determination of (E)-5-(2-bromovinyl)-2'-deoxyuridine in plasma and urine by capillary electrophoresis.
Olgemöller J; Hempel G; Boos J; Blaschke G
J Chromatogr B Biomed Sci Appl; 1999 Apr; 726(1-2):261-8. PubMed ID: 10348194
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bromovinyldeoxyuridine in the treatment of herpes simplex virus and varicella-zoster virus eye infections.
Maudgal PC; De Clercq E; Missotten L
Antiviral Res; 1984 Oct; 4(5):281-91. PubMed ID: 6335020
[TBL] [Abstract][Full Text] [Related]
18. Novel mouse models for the investigation of experimental drugs with activity against human varicella-zoster virus.
Weber O
Antivir Chem Chemother; 2000 Jul; 11(4):283-90. PubMed ID: 10950390
[TBL] [Abstract][Full Text] [Related]
19. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Balzarini J; Sienaert R; Liekens S; Van Kuilenburg A; Carangio A; Esnouf R; De Clercq E; McGuigan C
Mol Pharmacol; 2002 May; 61(5):1140-5. PubMed ID: 11961132
[TBL] [Abstract][Full Text] [Related]
20. [Mechanisms of antiherpes drugs and drug resistant virus--effect of BVDU on varicella zoster virus replication].
Shigeta S; Yokota T
Rinsho Byori; 1985 Feb; 33(2):148-57. PubMed ID: 2987573
[No Abstract] [Full Text] [Related]
[Next] [New Search]
